Aura Biosciences, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

AURA$7.66+16.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	December 31, 2025	December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$59,515	$31,693
Marketable securities	84,726	119,401
Prepaid expenses and other current assets	5,498	9,529
Total current assets	149,739	160,623
Restricted cash and deposits	768	768
Right-of-use assets - operating lease	15,828	17,379
Other long-term assets	471	518
Property and equipment, net	2,624	3,215
Total Assets	$169,430	$182,503
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	1,549	2,304
Short-term operating lease liability	3,243	3,149
Accrued expenses and other current liabilities	13,591	9,460
Total current liabilities	18,383	14,913
Long-term operating lease liability	14,134	15,620
Total Liabilities	32,517	30,533
Commitments and Contingencies (Note 12)
Stockholders’ Equity:
Common stock, $0.00001 par value, 150,000,000 authorized at December 31, 2025 and December 31, 2024, and 63,587,777 and 49,998,279 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	—	—
Additional paid-in capital	617,433	525,934
Accumulated deficit	(480,418)	(374,227)
Accumulated other comprehensive income (loss)	(102)	263
Total Stockholders’ Equity	136,913	151,970
Total Liabilities and Stockholders’ Equity	$169,430	$182,503

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.